Novel TLR2xTLR4 Bispecific Antibody Inhibits Bacterial Sepsis.
Novel TLR2xTLR4 Bispecific Antibody Inhibits Bacterial Sepsis.
Monoclon Antib Immunodiagn Immunother. 2020 Dec 21;:
Authors: Sato M, Takeuchi S, Moriya R, Kito T, Soga S, Aoyama K, Suzuki J
Abstract
Toll-like receptors (TLRs) sense microbial infection through recognition of pathogen-associated molecular patterns. For example, TLR4 responds to the lipopolysaccharide of gram-negative bacteria, whereas TLR2 recognizes a broad range of microbial ligands. Both receptors are, therefore, compelling targets for treating sepsis. Here, we developed a TLR2xTLR4 tetravalent bispecific antibody designated ICU-1, which inhibits both receptors. The inhibitory activity of ICU-1 was comparable to that of the parental antibodies in neutralization assays using a human monocyte cell line. Moreover, ICU-1 completely blocked stimulation of human peripheral blood mononuclear cells by clinically relevant bacterial species. These findings provide convincing evidence that ICU-1 offers a novel approach for treating bacterial sepsis.
PMID: 33347385 [PubMed - as supplied by publisher]
Source: Monoclonal Antibodies in Immunodiagnosis and Immunotherapy - Category: Microbiology Tags: Monoclon Antib Immunodiagn Immunother Source Type: research
More News: Immunotherapy | Microbiology